Article History
Received: 25 June 2018
Revised: 29 January 2019
Accepted: 1 February 2019
First Online: 6 March 2019
Competing interests
: T.E.K. and K.P.B. declare no competing interests. E.M.V.A. holds consulting roles with Tango Therapeutics, Invitae, Genome Medical, Illumina, Foresite Capital, and Dynamo, receives research support from Bristol-Myers Squibb and Novartis, owns equity in Tango Therapeutics, Genome Medical, Syapse, and Microsoft, received travel reimbursement from Roche/Genentech, and is on an institutional patent for chromatin mutations and immunotherapy response.